Cargando…
Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State
Respiratory syncytial virus infection (RSVI) is an acute medical and social problem in many countries globally. Infection is most dangerous for infants under one year old and the elderly. Despite its epidemiological relevance, only two drugs are registered for clinical use against RSVI: ribavirin (a...
Autores principales: | Shtro, Anna A., Petukhova, Galina D., Romanova, Aleksandra S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9000545/ https://www.ncbi.nlm.nih.gov/pubmed/35408661 http://dx.doi.org/10.3390/molecules27072263 |
Ejemplares similares
-
Monoterpene-Containing Substituted Coumarins as Inhibitors of Respiratory Syncytial Virus (RSV) Replication
por: Khomenko, Tatyana M., et al.
Publicado: (2021) -
Discovery of N-Containing (-)-Borneol Esters as Respiratory Syncytial Virus Fusion Inhibitors
por: Sokolova, Anastasiya S., et al.
Publicado: (2022) -
Current State of Respiratory Syncytial Virus Disease and Management
por: Chatterjee, Archana, et al.
Publicado: (2021) -
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
por: Biagi, Carlotta, et al.
Publicado: (2020) -
Respiratory syncytial virus: current and emerging treatment options
por: Turner, Tiffany L, et al.
Publicado: (2014)